Day 1 :
Keynote Forum
Ting-Chao Chou
PD Science LLC,USA
Keynote: Efficacy, Safety, Economy and Regulatory Consequences of Antiviral Agents
Time : 09:40-10:20
Biography:
Ting-Chao Chou (born in Taiwan), received M.S in pharmacology, National Taiwan University, Ph.D. in Pharmacology from Yale University in 1970, and postdoctoral fellowship from Johns Hopkins University School of Medicine. Member of Sloan-Kettering Cancer Center (MSKCC) and Professor of Pharmacology at Cornell University Graduate School of Medical Sciences. He is Honorary Professor at Chinese Academy of Medical Sciences (1993-) and Visiting Professor at five universities. He was Director of Preclinical Pharmacology Core at MSKCC where he retired on June 1st, 2013. Dr. Chou published >300 articles, have been cited 22,589 times in 850 different bio-medical journals, with h-index: 65, based on Google Scholar Citations. He is inventor/co-inventor of 38 U.S. Patents. Dr. Chou is the Founder of PD Science, LLC., USA
Abstract:
There are three primary determinants of the success for the development of any therapeutic new drugs: Efficacy, Safety and Economy without an exception. The first two priorities determine the usefulness, and the third determines affordability and beneficial to a large number of people and yet at reasonable cost and financial return to the pharmaceutical developers. Hundreds of thousands of scientists are searching for potent and effective compounds, and equally important to pursue low toxicity and tolerable side effects. For anti-viral agents such as AIDS therapy, several unique aspects need to be considered: i) The known etiological pathogens and its life cycle steps for targeting, such as HIV; ii) HIV has high mutation rates that resulted in drug resistance; iii) There are only very limited and costly animal models available so that need to stress quantitative and sensitive in vitro evaluation of candidate compounds for preclinical development and clinical follow-ups. Many of the above conditions have been met, but many others remain difficult and pose uncertainties. For today’s discussion, the author would like to focus on the following questions: i) Why we need drug combinations such as cocktails for antivirals? ii) How to design, and quantitatively determine and rank them with computerized simulations? iii) Are the currently approved anti-HIV combination patents and their FDA approved anti-HIV products really represent the better or the best therapeutic products? All the above questions will be discussed and answered by the unified theory of the median-effect equation of the mass-action law, the combination-index theorem, and their computerized simulations using the CompuSyn software. This software preciously cost $399 each license (2005-2012), is now offered for free download, upon registration, beginning 8.1.2012 via www.combosyn.com for broad bio-medical and pharmaceutical applications. The free downloads, as of 4.11.2016, has reached > 14,200 by scientists from 97 countries or territories
Keynote Forum
Ronald Moss
Ansun Biopharma, USA
Keynote: DAS181: A Novel Host Directed Approach to Prevent and Treat Severe Respiratory Virus Infections
Time : 10:20-11:00
Biography:
Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology.
Abstract:
Vaccines and virus specific antivirals are currently the main approaches to prevent and treat respiratory virus infections. DAS181, a novel inhaled sialidase fusion protein, has shown in vitro and in vivo activity against many subtypes and strains influenza virus including H7N9, H5N1. In addition DAS181 has shown in vitro and in vivo activity against parainfluenza virus strains (PIV-1, PIV-2, PIV-3, and PIV-4) virus, and EV68, by inactivating the virus binding receptors. For parainfluenza, significant morbidity and mortality is observed in immunosuprressed transplant patients without any licensed vaccines or antiviral drugs. Recent data also suggests that DAS181 has activity against two important respiratory viruses, Respiratory Syncytial Virus (RSV), and Metapneumovirus. The host directed approach of DAS181 contrasts virus specific antivirals, by potentially circumventing considerable issues related to antiviral drug resistance and prediction of strains required for vaccines. DAS181, an investigational drug, is currently in phase 2 clinical trials of PIV infection. DAS181 has the potential to be utilized against a broad spectrum of severe respiratory infections. Preclinical and clinical data from studies of DAS181 will be presented.